Consultation record

Submissions not accepted — page 2

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

147 documents · page 2 of 5

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-PEOPLE-REGIS/009	Draft policy on the register of members and reviewers	Hortensia Beauchamp-Ekong	Recusal should follow automatically from any declared financial interest
DRAFT-CORRECTIONS-/017	Draft corrections and versioning policy	Dr Liesbeth Quenneville	Anonymous submissions should be accepted where the respondent risks employment consequences
DRAFT-CORRECTIONS-/008	Draft corrections and versioning policy	Dr Theodora Trelawney	The document set should be published in translation
DRAFT-STABILITY-ST/013	Draft standard: freeze–thaw and in-use stability assessment of…	Quentin Gwynne-Sarpong	The document should state what a reader ought to do
DRAFT-INDICATION-S/002	Draft indication set and anchor outcomes	Dr Kamila Ubertini industry	The document should not describe uses outside the approved indication
DRAFT-MASH-SYNTHES/004	Draft synthesis: incretin receptor agonists for metabolic…	Dr Jacinta Steenkamp-Ferreira	The review question is drawn too broadly to be answerable
DRAFT-ADOLESCENT-S/007	Draft synthesis: incretin receptor agonists in adolescents	Dr Gervase Abergavenny	The review question is drawn too broadly to be answerable
DRAFT-ADOLESCENT-S/002	Draft synthesis: incretin receptor agonists in adolescents	Dr Liesbeth Nyquist-Obiora	The document should state what a reader ought to do
DRAFT-ANALYTICAL-S/003	Draft analytical review: surveys of unregulated peptide supply	Dr Zdenka Nyquist-Obiora	The document should state what a reader ought to do
DRAFT-ANALYTICAL-S/002	Draft analytical review: surveys of unregulated peptide supply	Professor Bartolomeu Nkosi-Lindegaard	The review question is drawn too broadly to be answerable
DRAFT-REGISTRY-STR/006	Draft structure of the document registry	Dr Anselm Thorsby-Nakamura	The document should state what a reader ought to do
DRAFT-TOOLS-DISCLA/008	Draft terms for the Institute’s calculators	Dr Stellan Cholmondeley-Ade	The document should state what a reader ought to do
DRAFT-TOOLS-DISCLA/006	Draft terms for the Institute’s calculators	Dr Ndidi Ravensworth-Ilunga industry	The document should not describe uses outside the approved indication
DRAFT-TOOLS-DISCLA/004	Draft terms for the Institute’s calculators	Vittoria Quintanilha	Recusal should follow automatically from any declared financial interest
DRAFT-ORFORGLIPRON/008	Draft monograph: orforglipron	Dr Jerome Lavrentiev	The document set should be published in translation
DRAFT-ORFORGLIPRON/002	Draft monograph: orforglipron	Dr Wolfram Tollemache industry	The document should not describe uses outside the approved indication
DRAFT-METHODOLOGY-/001	Draft methodology document, version 4	Dr Theodora Ingelbrecht industry	The document should not describe uses outside the approved indication
DRAFT-METHODOLOGY-/016	Draft methodology document, version 4	Dr Ludmila Tollemache	The document should state what a reader ought to do
DRAFT-METHODOLOGY-/004	Draft methodology document, version 4	Dr Jerome Petrossian	The document set should be published in translation
DRAFT-SUPPLIERS-CO/005	Draft supplier comparison table	Professor Ekaterina Voskresenskaya-Hill industry	The document should not describe uses outside the approved indication
DRAFT-RETATRUTIDE-/006	Draft monograph: retatrutide	Dr Katarzyna Yorkstone	The monograph should state what the compound costs
DRAFT-RETATRUTIDE-/012	Draft monograph: retatrutide	Dr Melisande Kirkpatrick-Ola	The document set should be published in translation
DRAFT-RETATRUTIDE-/010	Draft monograph: retatrutide	Dr Kolawole Isaksen-Balogun industry	The document should not describe uses outside the approved indication
DRAFT-MELANOCORTIN/005	Draft scoping review: melanocortin receptor agonists	Dr Jolanta Uttridge	The document should state what a reader ought to do
DRAFT-SEARCH-STRAT/016	Draft search-strategy template for the synthesis series	Dr Zofia Petrossian	The document should state what a reader ought to do
DRAFT-SEARCH-STRAT/014	Draft search-strategy template for the synthesis series	Professor Bartolomeu Nkosi-Lindegaard	The document set should be published in translation
DRAFT-PRINT-AND-AR/003	Draft print and archival format for Institute documents	Dr Kolawole Isaksen-Balogun	The document should state what a reader ought to do
DRAFT-PRINT-AND-AR/018	Draft print and archival format for Institute documents	Vittoria Quintanilha	Anonymous submissions should be accepted where the respondent risks employment consequences
DRAFT-PRINT-AND-AR/007	Draft print and archival format for Institute documents	Dr Emiliana Ollerenshaw	Recusal should follow automatically from any declared financial interest
DRAFT-PRINT-AND-AR/001	Draft print and archival format for Institute documents	Dr Ilona Mbatha-Fredriksen industry	The document should not describe uses outside the approved indication

page 2 of 5